{
  "docId": "019de075-03fc-75b4-9b20-1ad4baba72b2",
  "docSlug": "9cc11288f450409d9a3eef75fc694943",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 39,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 25,
  "notes": "The slide uses three distinct chart types to demonstrate efficacy, pharmacokinetics, and selectivity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-03fc-75b4-9b20-1ad4baba72b2/30",
  "deckHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2",
  "deckJsonHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2.json",
  "deckAnchorHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.35,
        "x": 0.58,
        "y": 0.22
      },
      "kind": "chart",
      "text": "AVOIDING TRK INHIBITION",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d26a183e-9e63-4964-9f99-4ea7703bd0b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.15,
        "x": 0.41,
        "y": 0.22
      },
      "kind": "chart",
      "text": "BRAIN PENETRANCE",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8dbd98c9-0ff9-42e7-a98c-aa78e2c5d2f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.32,
        "x": 0.07,
        "y": 0.22
      },
      "kind": "chart",
      "text": "ACTIVITY AGAINST ALK WILD-TYPE AND MUTANTS",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad963a42-c970-46ab-a6ae-9f577836bfd5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.07,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "IC50, half-maximal inhibitory concentration; PO, orally; pTRK, BDNF-stimulated TRKB phosphorylation. Head-to-head clinical studies comparing NVL-655 with currently approved or investigational therapies have not been conducted. Above data from preclinical studies. Sources: Mizuta, H. et al., WCLC 2022; Pelish, H.E. et al., AACR 2021; Data on file.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3261306-3ee1-4cdb-aa60-4a8f4d764c79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.07,
        "y": 0.05
      },
      "kind": "title",
      "text": "Preclinical | NVL-655 is a Brain Penetrant, ALK-Selective Inhibitor with the Potential to Avoid TRK-Related CNS Adverse Events",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a17ceb7-5206-4db7-8b0e-982222da057e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chartjunk Elimination",
      "slug": "chartjunk-elimination",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "e34e09e7-7f47-4bca-b76c-5d75c74f730c",
      "evidence": "clear and simple charts used to display data",
      "confidence": 0.7
    },
    {
      "name": "Data-Ink Ratio",
      "slug": "data-ink-ratio",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "3d04f7cc-d544-4f7e-913f-18fa09c77688",
      "evidence": "charts appear to have a high data-ink ratio",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}